StockNews.com Initiates Coverage on Cancer Genetics (NASDAQ:CGIX)

Equities researchers at StockNews.com assumed coverage on shares of Cancer Genetics (NASDAQ:CGIX) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock.

Cancer Genetics Price Performance

Shares of NASDAQ:CGIX opened at $0.16 on Friday. The company has a market cap of $637,260.00, a P/E ratio of -0.08 and a beta of 2.72. Cancer Genetics has a 1-year low of $2.11 and a 1-year high of $17.50.

About Cancer Genetics

Vyant Bio, Inc is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson’s Disease.